Wall Street's Growing Optimism Toward Abbott Laboratories
Abbott Laboratories (ABT) is gaining renewed attention from Wall Street due to stronger-than-expected earnings growth, particularly driven by its Medical Devices segment. In Q2 2026, the company reported a 13% sales increase and adjusted EPS of $1.31, leading it to raise full-year guidance for adjusted EPS between $5.45 and $5.60. Analysts have responded positively with upgraded ratings and higher price targets from firms like TD Cowen, Citi, and Wolfe Research. The Medical Devices segment is central to Abbott's growth story, contributing nearly half of its Q2 sales and showing 8.4% comparable growth. The company also recently acquired Exact Sciences for $21 billion, expanding into cancer diagnostics with products such as Cologuard. While this acquisition will initially weigh on earnings before cost savings materialize, it is expected to provide long-term value. Despite these positives, Abbott faces challenges due to uneven performance across its business segments and a relatively high valuation of 33 times earnings. However, the company's strong cash flow generation supports continued dividend growth, which has been raised for 54 consecutive years.
Topics: dividends healthcare medical devices